Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009

Journal of Hepatology

Volumn 53, Issue 2, 2010, Pages 230-237

  Cacoub, Patrice ^a,b   Halfon, Philippe ^c   Rosenthal, Eric ^d   Bailly, Franois ^e   Sadr, Firouze Bani ^f   Benhamou, Yves ^b   Chevaliez, Stéphane ^g   Pawlotsky, Jean Michel ^g   Piroth, Lionel ^h   Yazdanpanah, Yazdan ⁱ   Pol, Stanislas ^j  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Laboratoire Alphabio   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e HÔTEL DIEU   (France)

^f HÔPITAL TENON   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h Service de Maladies Infectieuses   (France)

ⁱ Maladies Infectieuses   (France)

^j Université René Descartes Paris v ^*  (France)

more..

Author keywords

Coinfection; HCV; HIV; Interferon; Treatment

Indexed keywords

ALCOHOL; CD4 ANTIGEN; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; BIOPSY; BLOOD; COMORBIDITY; FRANCE; HEALTH SURVEY; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TRENDS; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOPSY; COMORBIDITY; FEMALE; FRANCE; HEALTH SURVEYS; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LIVER; MALE; MIDDLE AGED; PATIENT CARE MANAGEMENT; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 77955308037     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.03.009     Document Type: Article

References (61)

1. P. Cacoub, L. Geffray, E. Rosenthal, C. Perronne, P. Veyssier, and G. Raguin Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997 Clin Infect Dis 32 2001 1207 1214
2. E. Rosenthal, M. Poirée, C. Pradier, C. Perronne, D. Salmon-Ceron, and L. Geffray Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) AIDS 17 2003 1803 1809
3. C. Jaggy, J. von Overbeck, B. Ledergerber, C. Schwarz, M. Egger, and M. Rickenbach Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population Lancet 362 2003 877 878 (Pubitemid 37130098)
4. E. Rosenthal, D. Salmon-Céron, C. Lewden, V. Bouteloup, G. Pialoux, and F. Bonnet Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19) HIV Med 10 2009 282 289
5. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009 Jun 19 [Epub ahead of print].
6. M.S. Sulkowski Viral hepatitis and HIV coinfection J Hepatol 48 2008 353 367
7. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
8. R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, and K.E. Sherman PEG-interferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons N Engl J Med 351 2004 451 459
9. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh, E. Lissen, J. Gonzalez-Garcia, and A. Lazzarin Peginterferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin in HIV-infected patients N Engl J Med 351 2004 438 450
10. F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, and A. Benzekri A randomized controlled trial of pegylated interferon alfa-2b plus ribavirin versus standard interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in HIV-infected patients (RIBAVIC-ANRS HC02) JAMA 292 2004 2839 2848
11. M. Laguno, J. Murillas, J.L. Blanco, E. Martinez, R. Miquel, and J.M. Sanchez-Tapias Peginterferon-alfa-2b plus ribavirin versus interferon-alfa-2b plus ribavirin for treatment of HIV-HCV co-infected patients AIDS 18 2004 F27 F36
12. J. Berenguer, J. Alvarez-Pellicer, P.M. Martín, J. López-Aldeguer, M.A. Von-Wichmann, and C. Quereda Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
13. M. Laguno, C. Cifuentes, J. Murillas, S. Veloso, M. Larrousse, and A. Payeras Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients Hepatology 49 2009 22 31
14. E. Righi, A. Beltrame, M. Bassetti, V. Lindstrom, G. Mazzarello, and C. Dentone Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort Infection 36 2008 358 361
15. M. Crespo, J.A. Mira, J.A. Pineda, E. Van den Eynde, M.J. Ríos-Villegas, and A. Collado Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen J Antimicrob Chemother 62 2008 793 796
16. C.A. Fleming, D.E. Craven, D. Thornton, S. Tumilty, and D. Nunes Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment Clin Infect Dis 36 2003 97 100
17. P. Cacoub, E. Rosenthal, P. Halfon, D. Sene, C. Perronne, and S. Pol Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life J Viral Hepat 13 2006 678 682
18. S.H. Mehta, G.M. Lucas, L.B. Mirel, M. Torbenson, Y. Higgins, and R.D. Moore Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic AIDS 20 2006 2361 2369
19. D. Nunes, R. Saitz, H. Libman, D.M. Cheng, J. Vidaver, and J.H. Samet Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems Alcohol Clin Exp Res 30 2006 1520 1526 (Pubitemid 44272741)
20. B.R. Edlin, T.F. Kresina, D.B. Raymond, M.R. Carden, M.N. Gourevitch, and J.D. Rich Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users Clin Infect Dis 40 2005 S276 S285
21. H. Scheft, and D.C. Fontenette Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital Clin Infect Dis 40 2005 S292 S296
22. P. Cacoub, P. Halfon, E. Rosenthal, G. Pialoux, Y. Benhamou, and C. Perronne Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006 J Hepatol 48 2008 35 42
23. A.A. Butt, U.A. Khan, O.S. Shaikh, D. McMahon, Z. Dorey-Stein, and J. Tsevat Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers HIV Clin Trials 10 2009 25 32
24. M. McLaren, G. Garber, and C. Cooper Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic Can J Gastroenterol 22 2008 133 137
25. J. Grebely, K.A. Genoway, J.D. Raffa, G. Dhadwal, T. Rajan, and G. Showler Barriers associated with the treatment of hepatitis C virus infection among illicit drug users Drug Alcohol Depend 93 2008 141 147
26. A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren, and G. Palu Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients J Hepatol 42 2005 615 624
27. J. Rockstroh, S. Bhagani, Y. Benhamou, R. Bruno, S. Mauss, and L. Peters EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults HIV Med 9 2008 82 88
28. P. Cacoub, F. Carrat, P. Bédossa, J. Lambert, G. Pénaranda, and C. Perronne Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study - ANRS HC02 J Hepatol 48 2008 765 773
29. P. Halfon, F. Carrat, P. Bédossa, J. Lambert, G. Pénaranda, and C. Perronne Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the fibrovic 2 study - ANRS HC02 Antivir Ther 14 2009 211 219
30. V. de Lédinghen, C. Douvin, A. Kettaneh, M. Ziol, D. Roulot, and P. Marcellin Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients J Acquir Immune Defic Syndr 41 2006 175 179
31. G.D. Kirk, J. Astemborski, S.H. Mehta, C. Spoler, C. Fisher, and D. Allen Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection Clin Infect Dis 48 2009 963 972
32. P. Cals, F. Oberti, S. Michalak, I. Hubert-Fouchard, M.C. Rousselet, and A. Konaté A novel panel of blood markers to assess the degree of liver fibrosis Hepatology 42 2005 1373 1381
33. D.L. Suzman, M. McLaughlin, Z. Hu, D.E. Kleiner, B. Wood, and R.A. Lempicki Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach AIDS 22 2008 1433 1439
34. P.C. Tien Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office Am J Gastroenterol 100 2005 2338 2354
35. K. Falconer, J.K. Sandberg, O. Reichard, and A. Alaeus HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment Scand J Infect Dis 26 2009 1 5
36. I. Maida, V. Soriano, B. Ramos, P. Rios, J. Gonzalez-Lahoz, and M. Nunez Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center HIV Clin Trials 6 2005 329 336
37. S.H. Mehta, B.L. Genberg, J. Astemborski, R. Kavasery, G.D. Kirk, and D. Vlahov Limited uptake of hepatitis C treatment among injection drug users J Community Health 33 2008 126 133
38. J. Grebely, J.D. Raffa, C. Lai, M. Krajden, T. Kerr, and B. Fischer Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents J Viral Hepat 16 2009 352 358
39. A. Mocroft, J. Rockstroh, V. Soriano, O. Kirk, J.P. Viard, and S. Caplinskas EuroSIDA Study Group. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C Scand J Infect Dis 38 2006 1092 1097
40. C.L. Cooper, and D.W. Cameron Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV Clin Infect Dis 41 2005 S105 S109
41. D.M. Novick, and M.J. Kreek Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients Addiction 103 2008 905 918
42. Lang JP, Melin P, Ouzan D, Rotily M, Fontanges T, Marcellin P, et al. Peginterferon alfa-2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antivir Ther, in press.
43. M.B. Klein, C. Cooper, M.J. Brouillette, N.L. Sheehan, C. Benkelfat, and L. Annable CTN194 Investigators. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy Contemp Clin Trials 29 2008 617 630
44. F. Bani-Sadr, I. Goderel, C. Penalba, E. Billaud, J. Doll, and Y. Welker ANRS HC02 - Ribavic Study team. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin J Viral Hepat 14 2007 639 644
45. V. Soriano, C. Miralles, M.A. Berdún, E. Losada, K. Aguirrebengoa, and A. Ocampo PRESCO Study Group. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin Antivir Ther 12 2007 469 476
46. P.J. Pockros, M.L. Shiffman, E.R. Schiff, M.S. Sulkowski, Z. Younossi, and D.T. Dieterich PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
47. M. Núnez, N. Camino, B. Ramos, M.A. Berdún, P. Barreiro, and E. Losada Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C Antivir Ther 10 2005 657 662
48. L. Piroth, B. Martha, A. Minello, M. Grappin, and P. Chavanet Treatment of chronic hepatitis C in HIV-infected patients: from clinical trials to field practice Scand J Infect Dis 40 2008 561 564
49. F. Bani-Sadr, N. Lapidus, P. Bedossa, C.M. De Boever, C. Perronne, and P. Halfon French National Agency for Research on AIDS; Viral Hepatitis-HC02- Ribavic Study Team. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors Clin Infect Dis 46 2008 768 774
50. M.S. Sulkowski, S.H. Mehta, M.S. Torbenson, Y. Higgins, S.C. Brinkley, and R.M. de Oca Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults AIDS 21 2007 2209 2216
51. D. Salmon-Ceron, E. Rosenthal, C. Lewden, V. Bouteloup, T. May, and C. Burty ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study J Hepatol 50 2009 736 745
52. G.W. Neff, N.J. Shire, and S.M. Rudich Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus Clin Infect Dis 41 2005 S50 S55
53. J.C. Duclos-Vallée, C. Féray, M. Sebagh, E. Teicher, A.M. Roque-Afonso, and B. Roche THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 47 2008 407 417
54. M. Testillano, J.R. Fernandez, M.J. Suarez, M. Gastaca, J. Bustamante, and J.I. Pijoan Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center Transplant Proc 41 2009 1041 1043
55. C. Tan-Tam, L. Frassetto, and P. Stock Liver and kidney transplantation in HIV-infected patients AIDS Rev 11 2009 190 204
56. M. Opravil, J. Sasadeusz, D.A. Cooper, J.K. Rockstroh, N. Clumeck, and B. Clotet Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40 kDa) plus ribavirin in patients with HIV/hepatitis C virus coinfection J Acquir Immune Defic Syndr 47 2008 36 49
57. L. Valerio, Y. Yazdanpanah, I. Poizot-Martin, E. Rosenthal, C. Marimoutou, and J.A. Gastaut Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients J Acquir Immune Defic Syndr 47 2008 50 55
58. J.A. Pineda, J.A. García-García, M. Aguilar-Guisado, M.J. Ríos-Villegas, J. Ruiz-Morales, and A. Rivero Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy Hepatology 46 2007 622 630
59. J.F. Pascual-Pareja, A. Caminoa, C. Larrauri, J. González- García, M.L. Montes, and J. Díez HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy AIDS 23 2009 971 975
60. E. Vispo, P. Barreiro, J.A. Pineda, J.A. Mira, I. Maida, and L. Martín-Carbonero Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir Antivir Ther 13 2008 429 437 (Pubitemid 352016736)
61. Perrella A, Sbreglia C, D'Antonio A, Atripaldi L, Perrella O. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. Clin Microbiol Infect 2009 [Epub ahead of print].